Twice Daily Revenue and Competitors

Location

N/A

Total Funding

Retail

Industry

Estimated Revenue & Valuation

  • Twice Daily's estimated annual revenue is currently $74.7M per year.(i)
  • Twice Daily's estimated revenue per employee is $249,700

Employee Data

  • Twice Daily has 299 Employees.(i)
  • Twice Daily grew their employee count by 19% last year.

Twice Daily's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$8M442%N/AN/A
#2
$7.8M438%N/AN/A
#3
$7.8M4348%N/AN/A
#4
$165.1M5827%N/AN/A
#5
$69.2M277-4%N/AN/A
#6
$280.6M88322%N/AN/A
#7
$6M333%N/AN/A
#8
$586.7M18466%N/AN/A
#9
$23.8M1059%N/AN/A
#10
$14.7M72-5%N/AN/A
Add Company

What Is Twice Daily?

Twice Daily delivers a differentiated food and fuel stop experience with fast, friendly service and quality convenience products for busy customers on the go. With a fresh-all-day menu, Twice Daily provides everything from premium morning coffee and handcrafted afternoon sandwiches to after-school snacks—ensuring customers stop by at least twice daily. Committed to being a good neighbor and building strong, lasting community relationships, every purchase made at Twice Daily helps support local jobs and local causes. Having served local communities since 2011, the brand currently has more than 50 locations across Middle Tennessee and parts of Kentucky.

keywords:N/A

N/A

Total Funding

299

Number of Employees

$74.7M

Revenue (est)

19%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Twice Daily News

2022-03-30 - Allergan's Twice-Daily Vuity Study Hits Main Endpoint in Presbyopia ABBV

By Colin Kellaher. AbbVie Inc.'s Allergan unit on Tuesday said a Phase 3 study of twice-daily use of its Vuity eye drops met the main...

2022-03-30 - Allergan, an AbbVie Company, Announces Positive Topline ...

Allergan, an AbbVie Company, Announces Positive Topline Phase 3 Results Evaluating Investigational Twice-Daily Administration of VUITY™ (...

2022-03-30 - Twice-daily Vuity meets primary endpoint in phase 3 ...

Twice-daily Vuity for presbyopia met its primary efficacy endpoint in the phase 3 VIRGO trial, according to a press release from...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$33M3009%N/A
#2
$82.8M30038%N/A
#3
$35M300-1%N/A
#4
$66.1M302N/AN/A
#5
$116.7M3066%N/A